Overview

Weight Gain Management in Patients With Schizophrenia

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Nizatidine
Olanzapine